Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014

被引:107
|
作者
Bai, Chang-Qing [1 ]
Mu, Jin-Song [2 ]
Kargbo, David [3 ]
Song, Ya-Bin [4 ]
Niu, Wen-Kai [1 ]
Nie, Wei-Min [2 ]
Kanu, Alex [5 ]
Liu, Wei-Wei [1 ]
Wang, Yao-Ping [6 ]
Dafae, Foday [3 ]
Yan, Tao [2 ]
Hu, Yi [4 ]
Deng, Yong-Qiang [4 ]
Lu, Hui-Jun [7 ]
Yang, Fan [8 ,9 ]
Zhang, Xiao-Guang [10 ]
Sun, Yang [7 ]
Cao, Yu-Xi [10 ]
Su, Hao-Xiang [8 ,9 ]
Sun, Yu [6 ]
Liu, Wen-Sen [7 ]
Wang, Cheng-Yu [7 ]
Qian, Jun [7 ]
Liu, Liu [1 ]
Wang, Hong [4 ]
Tong, Yi-Gang [4 ]
Liu, Ze-Yuan [1 ]
Chen, Yun-Song [1 ]
Wang, Hong-Quan [4 ]
Kargbo, Brima [3 ]
Gao, George F. [11 ]
Jiang, Jia-Fu [4 ]
机构
[1] 307 Hosp, Beijing, Peoples R China
[2] 302 Hosp, Beijing, Peoples R China
[3] Sierra Leone Minist Hlth & Sanitat, Freetown, Sierra Leone
[4] Beijing Inst Microbiol & Epidemiol, Beijing, Peoples R China
[5] Sierra Leone China Friendship Hosp, Freetown, Sierra Leone
[6] Kingharman Rd Hosp, Freetown, Sierra Leone
[7] Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun, Peoples R China
[8] Chinese Acad Med Sci, Beijing, Peoples R China
[9] Peking Union Med Coll, Beijing, Peoples R China
[10] Inst Viral Dis Control & Prevent, Beijing, Peoples R China
[11] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China
基金
美国国家科学基金会;
关键词
Ebola virus disease; favipiravir; treatment; clinical features; Sierra Leone; T-705; FAVIPIRAVIR; SIERRA-LEONE; MOUSE MODEL; INFECTION; EFFICACY; OUTBREAK;
D O I
10.1093/cid/ciw571
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. During 2014-2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently. Methods. A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Patients with confirmed EVD were sequentially enrolled and treated with either World Health Organization (WHO)-recommended supportive therapy (control group) from 10 to 30 October, or treated with WHO-recommended therapy plus favipiravir (T-705) from 1 to 10 November 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group. Results. The overall survival rate in the T-705 treatment group was higher than that of the control group (56.4% [22/39] vs 35.3% [30/85]; P=.027). Among the 35 patients who finished all designed endpoint observations, the survival rate in the T-705 treatment group (64.8% [11/17]) was higher than that of the control group (27.8% [5/18]). Furthermore, the average survival time of the treatment group (46.9 +/- 5.6 days) was longer than that of the control group (28.9 +/- 4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had a >100-fold viral load reduction, compared with only 16.7% of patients in the control group. Conclusions. Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD.
引用
收藏
页码:1288 / 1294
页数:7
相关论文
共 50 条
  • [1] Theoretical investigation of the derivatives of favipiravir (T-705) as potential drugs for Ebola virus
    Rhyman, Lydia
    Tursun, Mahir
    Abdallah, Hassan H.
    Choong, Yee Siew
    Parlak, Cemal
    Kharkar, Prashant
    Ramasami, Ponnadurai
    [J]. PHYSICAL SCIENCES REVIEWS, 2018, 3 (09)
  • [2] Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus
    Bixler, Sandra L.
    Bocan, Thomas M.
    Wells, Jay
    Wetzel, Kelly S.
    Van Tongeren, Sean A.
    Dong, Lian
    Garza, Nicole L.
    Donnelly, Ginger
    Cazares, Lisa H.
    Nuss, Jonathan
    Soloveva, Veronica
    Koistinen, Keith A.
    Welch, Lisa
    Epstein, Carol
    Liang, Li-Fang
    Giesing, Dennis
    Lenk, Robert
    Bavari, Sina
    Warren, Travis K.
    [J]. ANTIVIRAL RESEARCH, 2018, 151 : 97 - 104
  • [3] Theoretical investigation of the derivatives of favipiravir (T-705) as potential drugs for Ebola virus
    Rhyman, Lydia
    Tursun, Mahir
    Abdallah, Hassan H.
    Choong, Yee Siew
    Parlak, Cemal
    Kharkar, Prashant
    Ramasami, Ponnadurai
    [J]. DENSITY FUNCTIONAL THEORY: ADVANCES IN APPLICATIONS, 2019, : 19 - 32
  • [4] Clinical Features of Patients With Ebola Virus Disease in Sierra Leone
    Qin, Enqiang
    Bi, Jingfeng
    Zhao, Min
    Wang, Ye
    Guo, Tongsheng
    Yan, Tao
    Li, Zhiwei
    Sun, Juan
    Zhang, Jieli
    Chen, Suhong
    Wu, Yao
    Li, Jin
    Zhong, Yanwei
    [J]. CLINICAL INFECTIOUS DISEASES, 2015, 61 (04) : 491 - 495
  • [5] Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
    Oestereich, Lisa
    Luedtke, Anja
    Wurr, Stephanie
    Rieger, Toni
    Munoz-Fontela, Cesar
    Guenther, Stephan
    [J]. ANTIVIRAL RESEARCH, 2014, 105 : 17 - 21
  • [6] Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus
    Bixler, Sandra L.
    Bocan, Thomas M.
    Wells, Jay
    Wetzel, Kelly S.
    Van Tongeren, Sean A.
    Garza, Nicole L.
    Donnelly, Ginger
    Cazares, Lisa H.
    Soloveva, Veronica
    Welch, Lisa
    Epstein, Carol
    Liang, Li-Fang
    Giesing, Dennis
    Lenk, Robert
    Bavari, Sina
    Warren, Travis K.
    [J]. ANTIVIRAL RESEARCH, 2018, 151 : 50 - 54
  • [7] Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
    Srinivasan, Kritika
    Rao, Mana
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2021, 8
  • [8] Clinical presentations and outcomes of patients with Ebola virus disease in Freetown, Sierra Leone
    Ying-Jie Ji
    Xue-Zhang Duan
    Xu-Dong Gao
    Lei Li
    Chen Li
    Dong Ji
    Wen-Gang Li
    Li-Fu Wang
    Yu-Hua Meng
    Xiao Yang
    Bin-Fang Ling
    Xue-Ai Song
    Mei-Lei Gu
    Tao Jiang
    She-Ku M. Koroma
    James Bangalie
    Hui-Juan Duan
    [J]. Infectious Diseases of Poverty, 5
  • [9] Clinical presentations and outcomes of patients with Ebola virus disease in Freetown, Sierra Leone
    Ji, Ying-Jie
    Duan, Xue-Zhang
    Gao, Xu-Dong
    Li, Lei
    Li, Chen
    Ji, Dong
    Li, Wen-Gang
    Wang, Li-Fu
    Meng, Yu-Hua
    Yang, Xiao
    Ling, Bin-Fang
    Song, Xue-Ai
    Gu, Mei-Lei
    Jiang, Tao
    Koroma, She-Ku M.
    Bangalie, James
    Duan, Hui-Juan
    [J]. INFECTIOUS DISEASES OF POVERTY, 2016, 5
  • [10] Ebola Virus Disease in Health Care Workers - Sierra Leone, 2014
    Kilmarx, Peter H.
    Clarke, Kevin R.
    Dietz, Patricia M.
    Hamel, Mary J.
    Husain, Farah
    McFadden, Jevon D.
    Park, Benjamin J.
    Sugerman, David E.
    Bresee, Joseph S.
    Mermin, Jonathan
    McAuley, James
    Jambai, Amara
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (49): : 1168 - 1171